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Abstract
Background: Insulin resistance is of utmost importance as an underlying mechanism for increased risk of
cardiovascular disease (CVD). We assessed the association between Homeostatic Model Assessment (HOMA-IR) and
two surrogate subclinical atherosclerosis markers (SCA) among individuals with and without type 2 diabetes (DM),
those who did not have any clinical presentation of the CVD.
Methods: In a cross-sectional study, 208 participants (105 diabetics and 103 non-diabetics) were enrolled from
referred patients with diabetes to an academic outpatient clinic and their non-diabetic relatives in-law. Fasting
serum levels of insulin, blood glucose and lipid profile, were measured. Anthropometric and blood pressure were
measuremented standardly. Body Mass Index (BMI) and Homeostatic Model Assessment-Insulin Resistance (HOMA-
IR) index were calculated. Coronary Artery Calcium Score(CACS) was measured using a Multi-Detctor CT scanner.
Flow mediated dilation (FMD) was measured using bimode ultrasonography (with linear transducer 13,000 MHZ).
Univariate and multivariate logistic regression models were used to evaluate the association between these SCA
markers and HOMA index in adjusting models.
Results: CACS and HOMA-IR were higher and FMD was lower in diabetic participants than non-diabetic ones (P < 0.
01) In a stepwise logistic regression model, CACS and FMD were associated with HOMA-IR (odds ratio = 1.778; 95 %
confidence interval (CI): 1.211–2.726 and odds ratio = 1.557; 95 % CI: 1.601–2.275, respectively) in non-diabetics but
not among diabetic participants.
Conclusions: CACS and FMD are related to insulin resistance among non-diabetic individuals, but we could not
find this relationship among diabetic patients.
Keywords: Coronary artery calcium score (CACS), Flow mediated dilation (FMD), Diabetes mellitus, Insulin
resistance, HOMA-IR, Atherosclerosis, Cardiovascular diseases
Background
Cardiovascular disease (CVD) is the leading cause of
mortality worldwide [1]. Atherogenesis initiates since
early life stages [2] and cardiovascular risk factors have
been present for many years before the clinical athero-
sclerosis becomes evident [3]. Diabetes mellitus is an
important risk factor for atheroma formation and ath-
erosclerosis progression [4].
Insulin resistance and the ensuing hyperinsulinemia/
hyperglycemia are critically important in increasing
CVD risk [5]. In fact insulin resistance is a crucial link
between diabetes and CVD [6]. Systemic insulin resist-
ance produces a proatherogenic lipid phenotype by in-
creasing very-low-density lipoprotein (VLDL) particles,
which are metabolized to remnant lipoproteins promot-
ing atherogenesis. Pro-inflammatory and pro-coagulant
states which are induced by insulin resistance, also play
important roles in atherogenesis [7].
* Correspondence: fakhrzad@tums.ac.ir
1Elderly Health Research Center, Endocrinology and Metabolism Population
Sciences Institute, Tehran University of Medical Sciences, Fourth Floor, No
4th, Ostad Nejatollahi Street, Enghelab Avenue, Tehran 15996615, Iran
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Fakhrzadeh et al. Journal of Diabetes & Metabolic Disorders  (2016) 15:41 
DOI 10.1186/s40200-016-0263-5
It is well established that patients with type 2 diabetes
have a higher prevalence of atherosclerosis as assessed
by carotid intima-media thickness [8]. Coronary artery
calcium score (CACS) is another surrogate atheroscler-
osis marker [9] which predicts coronary heart disease
(CHD) in both non-diabetics [10] and diabetics [11], by
visualizing coronary artery calcium. It is demonstrated
that CACS has an added value to the established criteria
of CHD identification [12]. Patients with a CACS ≥10
are at higher risk of CHD than those with CACS < 10
[13]. The results of the Framingham Offspring Study re-
vealed that subjects with insulin resistance and type 2
diabetes had an increased burden of atherosclerosis as
evidenced by higher CACS [14]. On the other hand, data
have indicated that alterations in endothelial function
may be followed by morphological changes that could
contribute to atherosclerosis progression [15]. Endothe-
lial dysfunction, proceeds by reduction of endothelium-
derived nitric oxide. Physical stimuli such as shear stress
and hypoxia could release nitric oxide from the endothe-
lial cells [16]. Flow mediated dilation (FMD) is a method
for measurement of the severity of vasodilation in re-
sponse to shear stress. FMD is usually measured by
computing the percent increase of brachial artery diam-
eter after inducing shear stress by closing a calf around
the arm [17].
Homeostatic model assessment (HOMA) index, is
widely used for the assessment of insulin resistance as a
valid surrogate of the gold standard method
hyperinsulinemic-euglycemic clamp [18]. While not yet
recommended for risk stratification, it is demonstrated
that HOMA index is a reliable tool for prediction of the
risk of coronary events [19]. It is also valuable for risk
stratification in patients with angographically docu-
mented CHD [20].
We aimed to evaluate the association between two
surrogate markers of atherosclerosis (CACS and FMD)
with HOMA index in non-diabetic and diabetic individ-
uals. We enroled both diabetic and non-diabetic subjects
because we thought that the effective factors affect sub-
clinical atherosclerosis may be differnet.
Methods
We enrolled 208 (105 diabetic and 103 non-diabic) indi-
viduals. The individual with diabetes was selected by a
systematic random method based on the patient ID code
of the eligible individuals. The diabetic participants were
recruited randomly from 20–70 year old patients with
type 2 diabetes, who referred between December 2011
till Augst 2012, to Dr. Shariati University hospital Dia-
betes Clinic. The non-diabetic subjects were selected
from non-bloody relations of diabetic participants (such
as their hausbands or wives), who did not have diabetes
in past medical history or in evaluations. The The
inclusion criteria of the study necessitated that the par-
ticipants be free of CVD or its symptoms. In addition
none of the participants had an abnormal electrocardio-
gram at the time of recruitment or history of diabetes
complications, as well (no sign of lower limb ischemia,
retinopathy, nephropathy and neuropathy). The non-
diabetic group were the relatives in-law of the diabetic
participants. Those having at least two fasting glucose
levels ≥126 mg/dl or using hypoglycemic agents, were
considered as diabetic [21]. Sex, age, and history of con-
suming anti-hypertensive drugs were documented in a
questionnaire filled out by a project assistant. Body mass
index (BMI) was calculated after weight and height were
measured using a calibrated electronic balance close to
0.1 Kg and a flexible tape to the accuracy of 0.5 cm. The
measurements were performed in light clothing without
shoes according to the standard methods. Smoking was
defined as smoking any number of cigarettes in the last
month prior to the study. After 15 min of rest in the sit-
ting position, blood pressure was recorded twice using
an automatic sphygmomanometer (Omron 7, Japan)
based on the Seventh Report of the Joint National Com-
mittee on Prevention, Detection, Evaluation, and Treat-
ment of High Blood Pressure (JNC7). Hypertension was
defined by a mean systolic blood pressure ≥ 140 mmHg
and/or a mean diastolic blood pressure ≥ 90 mmHg or
consuming anti hypertensive medications [22].
Lower limb ischemia, retinopathy, nephropathy and
neuropathy were ruled out by having an ankle brachial
index (ABI) between 0.91–1.30, normal retinoscopy, al-
bumin to creatine ratio < 30 mg/g in random spot urine
sample or glomerular filtration rate (GFR) > 90 ml/min/
1.73 m2 and normal monofilament 10 gr/diapason
250 Hz tests, respectively.
Using the photometry method (Pars Azmoon kits,
Iran/auto analyzer Hitachi 902, Japan), a complete lipid
profile was determined. Serum insulin levels were mea-
sured by radioimmunoassay method.
HOMA index was calculated using the following for-
mula [23]:
HOMA index ¼ plasma insulin mIU=Lð Þ  plasma glucose mg=dlð Þð  = 405½
Coronary Artery Calcium Score (CACS) measurement
Anterior-posterior and lateral chest scout views were ob-
tained. Calcium score images were obtained with a Phil-
lips 64 MDCT scanner using 64 × 2.5 mm × 400 ms with
120 KVP and 50–75 mAs to cover the entire heart and
proximal ascending aorta. A positive calcium score was
defined by 130 HU (Hounsfield units) with an area of
≥1 mm2. The amount of calcium was quantified using
the Agatston scoring method [24].
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Brachial Flow Mediated Dilation (FMD) measurement
We calculated the brachial artery FMD according to the
American College of Cardiology guidelines [25]. We de-
tected the edge of the borders of the brachial artery by a
software installed on a high resolution ultrasonography
device using a linear transducer 13,000 MHZ (MyLab 70
XVision, Biosound Esaote, USA). The measurement was
conducted on right brachial artery 3–5 cm above the
antecubital fossa just before cuff inflating and 60 s after
cuff release. A cuff was inflated at least 50 mmHg above
the systolic blood pressure around the right arm above
the antcubial fossa for 5 min to produce a transient is-
chemia. The brachial FMD was calculated as percentage
of alteration in brachial artery diameters induced by the
shearing stress. All the measurements were performed
in the end-diastolic phase coinciding with the R-wave of
electrocardiogram. The average of the measurements
during three consecutive cardiac cycles were considered
as the final FMD score.
Statistical analysis
SPSS software version 17.00 (SPSS Inc., Chicago, IL) was
used for statistical analysis and P-values < 0.05 were con-
sidered significant. After performing Kolmogorov-
Smirnov test to check the normality of the variables, we
found that the HOMA index was not normally distrib-
uted. The participants were categorized according to
CACS into two categories: CACS ≥ 10 and CACS < 10.
The student t-test and Mann–Whitney U-test were used
to compare the values between two groups. Both indi-
viduals with and without diabetes were classified into
two groups based on the first FMD quartile and other
participants. Skewed variables were reported as median
(range) and normally distributed variables as mean and
standard deviation (SD). Categorical variables were com-
pared by χ2 test. Univariabe binary logistic regression
model was used to demonstrate association between the
categorized CACS and FMD with HOMA index. We en-
tered HOMA index, age, sex, BMI, waist circumference,
HDL-C, hypertension and dyslipidemia, as predicting
factors in a multivariable binary logistic regression using
backward stepwise method (removed at 0.20 levels). Fi-
nally, for the categories of CACS in non-diabetic group
adjustment was performed for age and dyslipidemia and
in diabetic group correction was conducted for only age.
As well, for the classified FMD, in non-diabetic group,
the results were modified for age, sex, BMI, Waist cir-
cumference, and HDL-C. While in diabetic subjects this
adjustment was carried out for age, BMI, waist circum-
ference, and HDL-C.
Ethical considerations
This study was approved in the endocrinology and metab-
olism research Institute ethical committee. (Registration
code: 179/04/18/11). All stages of the study were con-
ducted according to the Helsinki declaration principles.
The participants signed the consent form after hearing the
explanation about the objectives and the methods of the
project by an experienced nurse. The confidentiality of
data was heeded at all stages of the study.
Results
A total of about 1500 diabetic cases referred to the dia-
betes clinic of Dr. Shariati hospital during the study
period, of whom 428 subjects were eligible. Of these,
294 individuals refrained to participate and 28 subjects
did not finish the data gathering process. Finally, 105
diabetic participants were enrolled. Also, we enrolled
103 non-diabetic individuals from in-law relatives of the
diabetic participants as controls. The demographic char-
acteristics of the participants is shown in Table 1.
More people in diabetic group than non diabetic group
had CACS ≥10 than in non-diabetics (37.1 %, n = 39 vs.
17.5 %, n = 18, respectively; P < 0.01). The values of CACS
were compared between two groups. There was a signifi-
cant difference between the values of CACS among the
diabetic and non diabetic groups (P < 0.01). Additionally,
there was a significant difference between diabetic and
non-diabetic participants in terms of FMD percents and
HOMA index values (P values < 0.01 for both). We found
a significant positive correlation between the HOMA
index and BMI, fasting blood sugar (FBS), Triglyceride
(TG), total cholesterol, low-density lipoprotein- choles-
terol (LDL-C) and age in the diabetic participants. How-
ever, we did not observe a significant correlation between
HOMA-IR and calcium score in individuals with diabetes
and also in those who were non-diabetic.
After categorizing patients according to CACS into
high risk and low risk groups for developing future CAD
(CACS ≥10 and CACS <10), in diabetic and non-
diabetic participants CACS was not significantly associ-
ated with HOMA index in a univariate logistic regres-
sion model, but it related to age in both groups. In
multivariable logistic model categorized CACS was re-
lated to the HOMA index after full adjustments in non-
diabetic group (odds ratio = 1.778; confidence interval
95 % 1.211–2.736) but there was no association between
CACS and HOMA- IR in diabetics (Table 2). Further-
more the categorized FMD had no relationship with
HOMA- IR in uniivarble model; While it was associated
with HOMA index after adjustment for potential con-
founders (odds ratio = 1.557; confidence interval 95 %
1.066–2.273) in non-diabetic group (Table 3).
Discussion
We found that CACS was related to HOMA-IR in non-
diabetics. By each unit increase of HOMA-IR, we found
more than 75 % increased risk of high CACS. This
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finding has a good concordance with the results of sev-
eral studies which notified a significant association be-
tween insulin resistance and CVD risk. For example
Bertoluci et al. showed that in patients with angiographic
CHD, a HOMA index > 6.0 was associated with life-
threatening coronary lesions and suggested the HOMA
index as an independent predictor of CHD [26]. In an-
other study in non-diabeticss, HOMA over 1.80 for
women and 2.12 for men was demonstrated to be pre-
dictive of increased risk of cardiovascular events and
mortality [27]. This relation has also been observed in
longitudinal population studies [15]. The Framingham
offspring researchers found a clear pattern of an increas-
ing burden of subclinical coronary atherosclerosis evi-
denced by higher CACS, with increasing severity of
glucose intolerance [15]. Lee et al. in a 24 month study
of 869 healthy adults aged 60 to 72 years who were free
of clinical CHD at enrollment, showed that Insulin re-
sistance independently predicted progression of CACS
[28]. Also in an older cohort, insulin resistance has been
suggested to increase CACS prevalence and progression
in both men and women [25]. Also a significant associ-
ation between advanced left anterior descending coron-
ary artery calcium deposition and glucose intolerance
(HBA1C ≥ 8.0). has been observed in the autopsy find-
ings of young adults [29]. Recently Sung et. al in a large
cohort of 10,511 young adult Korean men and women at
low risk for CVD found that insulin resistance was an
independent predictor of high CACS in men (P = 0.03);
with more impact on CVD risk and CACS in young
men compared with women. In this cohort diabetes was
also significantly associated with high CACS in men.
Men with diabetes had 3.8-fold increase in CACS preva-
lence compared with insulin sensitive men without dia-
betes. They suggested that individuals with early CACS
deposition are likely at the highest risk for future CHD
compared with their cohorts with low CACS [23].
On the other hand, we found that an increase in
HOMA-IR, was related to disturbance in FMD in the
nondiabetic participants. There are enormous clinical
and experimental studies which stipulate that insulin
Table 1 General Characteristics of the participants in two





N = 105 N = 103
Age year (mean ± SD) 54.06 ± 8.24 49.73 ± 6.77
Sex female 51.4 % 55.3 %
Smoking 9.5 % 1.0 %
Body Mass Index kg/m2
(mean ± SD)
27.65 ± 4.18 28.18 ± 4.45
Waist Circumference cm
(mean ± SD)
94.02 ± 10.71 92.44 ± 10.28
Hypertension 50.5 % 29.1 %
Low density Lipoprotein
mg/dl (mean ± SD)
95.96 ± 25.17 113.27 ± 22.09
High density Lipoprotein
mg/dl (mean ± SD)
41.22 ± 9.42 46.06 ± 11.09
Fasting Plasma Glucose mg/
dl (mean ± SD)
166.46 ± 62.30 95.72 ± 11.60
Insulin IU/L (mean ± SD) 9.12 ± 13.34 8.79 ± 6.12
HOMA Index (mean ± SD) 4.01 ± 7.77 2.10 ± 1.52
Flow Mediated Dilation %
(mean ± SD)
12.74 ± 6.76a 17.23 ± 10.05b
Coronary Artery Calcium
Score
118.58 ± 380.90 32.78 ± 108.39
SD standard deviation, HOMA
a N = 89
b N = 94
Table 2 Association between coronary artery calcium score categorized (≥10 and <10) with HOMA Index in univariate and
multivariable logistic regression modela
Univariabe model Multivariable model
Participants with diabetes Participants without diabetes Participants with diabetes Participants without diabetes
Odds ratio (CI 95 % odds ratio) Odds ratio (CI 95 % odds ratio) Odds ratio (CI 95 % odds ratio) Odds ratio (CI 95 % odds ratio)
HOMA 0.866 (0.717–1.046) 1.253(0.930–16.689) 0.960 (0.783–1.177) 1.778* (1.211–2.736)
Age 1.16* (1.083–1.238) 1.212* (1.097–1.339) 1.153* (1.076–1.236) 1.313* (1.147–1.501)
Sex (female) 0.606 (0.273–1.345) 0.588 (0.211–1.637) - -
BMI 0.976 (0.886–1.075) 1.062 (0.951–1.186) - -
6WC 0.983 (0.947–1.021) 1.096 (1.031–1.165) - -
HDL-C 1.006 (0.965–1.049) 1.023 (0.978–1.070) - -
Hypertension 2.041 (0.910–4.578) 2.291 (0.803–6.539) - -
Dyslipidemia 0.671 (0.295–1.526) 2.146 (0.737–6.247) - 4.323 (0.983–19.018)
Independent variables were Age, Sex, BMI, Waist Circumference, LDL-C, HDL-C, Hypertension, Hyperlipidemia
CI confidence interval, BMI body mass index, WC waist circumference, HDL-C high density lipoprotein cholesterol
*P < 0.05
a Backward Conditional Multivariable Logistic Regression Model (probability for stepwise: entry: 0.05 removal: 0.20)
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resistance might be a fundamental underlying metabolic
disturbance in CVD developmente. Furthermore, endo-
thelial dysfunction is one of the main components of of
insulin resistance [30]. Suzuki et al. in a study found that
insulin resistance was the sole predictor of FMD disturb-
ance [26].
We could not find any relationship between CACS
and FMD with insulin resistance among the diabetics.
There exists justifications for this apparent inconsist-
ency. First, estimation of insulin resistance based on
HOMA-IR in diabetic patients may be distorted due
to taking exogenous insulin with consequent develop-
ment of pseudohyperinsulinemia. Particularly, we did
not measure C-peptide [31]. Another explanation
could be that CACS and FMD in diabetic individuals
are related to several other factors; such as glycemic
control, diabetes duration, diabetes complications,
genetic factors, etc. which we were not able to in-
clude in our calculations, mainly due to limited sam-
ple size. These factors potentially confound the
relationship between insulin resistance and surrogate
atherosclerosis markers.
In general chronic subclinical inflammation due to in-
sulin resistance is potentially responsible for increased
CVD risk in those with hyperinsulinemia [32]. In animal
models insulin has been shown to enhance the prolifera-
tion of smooth muscle cells [33]. Chronic exposure to
advanced glycated end products with ensuing chronic
subclinical inflammatory signaling also plays important
roles in development of atherosclerosis in type 2 dia-
betics [34].
We used the cut off point of 10 (instead of 100) for
categorization of CACS; as there are studies which re-
port the cutoff of 10 to be more sensitive, albeit less spe-
cific for prediction of atherosclerosis [22]. Another
reason was that the number of non-diabetic individuals
with CACS ≥ 100 was few.
We also observed that the surrogate atherosclerosis
markers were related to age in both diabetic and non
diabetic participants. This finding was in concordance
with results of other studies which reported an associ-
ation between CAD and age [35].
Our finding of increased incidence of high CACS and
FMD in asymptomatic diabetic subjects relative to con-
trols was concordant with results of Schurgin et al. who
also showed an increased prevalence (26 %) of high
CACS in patients with diabetes compared to controls
(14 %, P < 0.004) [35]. Wagenknecht et al. also found an
increased prevalence (27 %) of high CACS in probands
of type 2 diabetics compared with nondiabetic siblings
(8 %, P < 0.003) [36]. Lately, researchers in the large
Multi-Ethnic Study of Atherosclerosis cohort showed
that individuals with MetS and DM have a greater inci-
dence and absolute progression of high CACS compared
with individuals without these conditions, with progres-
sion also predicting CHD events in those with MetS and
DM [37].
To our knowledge this is the first study in Iran, which
studies CACS and FMD as markers of atherosclerosis
among diabetic patients.
This study had limitations. First, this was a hospital-
based study with constraints to extend the results to the
population. Second, the sample size was not ideally large
which might bear some bias inherently as we were not
able to enter some other confounding factors such as dur-
ation of diabetes in our model. In addition this was a
cross-sectional study and causality interference is not pos-
sible for these types of studies. On the other hand, there
are other documented markers of atherosclerosis such as
carotid intima-media thickness (CIMT) which have been
Table 3 Association between Flow Mediated Dilation quartile (first and other quartiles) with HOMA Index in univariate and
multivariable logistic regression modela
Univariabe Model Multivariable Model
Participants with diabetes Participants without diabetes Participants with diabetes Participants without diabetes
Odds Ratio (CI 95 % odds ratio) Odds Ratio (CI 95 % odds ratio) Odds Ratio (CI 95 % odds ratio) Odds Ratio (CI 95 % odds ratio)
HOMA 0.978 (0.887–1.078) 1.177 (0.884–1.566) 0.973 (0.836–1.132) 1.557* (1.066–2.275)
Age 1.038 (0.980–1.101) 1.084* (1.002–1.172) 1.058 (0.990–1.132) 1.137* (1.021–1.265)
Sex (female) 0.859 (0.327–2.256) 0.204 (0.071–0.582) - 0.033 (0.004–0.310)
BMI 1.065 (0.952–1.191) 1.037 (0.935–1.150) 1.241 (0.997–1.546) 1.642* (1.179–2.289)
WC 0.977 (0.935–1.020) 1.027 (0.980–1.077) 0.925 (0.841–1.017) 0.817* (0.706–0.946)
HDL-C 0.937* (0.881–0.997) 0.919* (0.866–0.975) 0.912* (0.850–0.978) 0.905* (0.838–0.979)
Hypertension 2.208 (0.799–6.104) 2.265 (0.848–6.051) - -
Hyperlipidemia 1.394 (0.480–4.044) 0.596 (0.231–1.539) - -
Independent variables were Age, Sex, BMI, Waist Circumference, LDL-C, HDL-C, Hypertension, Hyperlipidemia
CI confidence interval, BMI body mass index, WC waist circumference, HDL-C high density lipoprotein cholesterol
*P < 0.05
aBackward Conditional Multivariable Logistic Regression Model (probability for stepwise: entry: 0.05 removal: 0.20)
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demonstrated to be of value in the assessment of the po-
tential risk for future cardiovascular events [38]. The other
weak point is a relatively wide variance in the duration of
diabetes among our diabetic group which could interfere
as a confounder in our investigation. We suggest future
studies with inclusion of other surrogate atherosclerosis
markers such as CIMT, and with larger sample size to
shed more light on the potential relationship between in-
sulin resistance and subclinical atherosclerosis.
Conclusion
Our study showed that the markers of subclinical ath-
erosclerosis such as CACS and FMD were related to in-
sulin resistance as indicated by increased HOMA index
among non-diabetic subjects but not in diabetics. This
finding could underline the role of insulin resistance in
developing the complications of atherosclerosis in non-
diabetic subjects. At the end, our observations imply
that measurement of serum insulin and calculation of
the HOMA index even in nondiabetic individuals may
have an added value to predict atherosclerosis over the
next years.
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